Program/Target Prog/Tgt
Indication Ind
Discovery Discov
Preclinical Preclin
Phase 1 Ph 1
Phase 2 Ph 2
Collaborations Collab
OKI-219
Breast cancer
OKI-219
PI3KαH1047R
selected inhibitor
Breast cancer
PIKture-01 Trial
PI3Kα is the most commonly mutated oncogene in cancer, with 14% of patients having mutations in this gene. PI3KαH1047R is by far the most common mutation, found in approximately 4% of all cancer and 15% of breast cancers, where it is associated with poor outcome and resistance to approved therapy.
PI3KαH1047R(next gen)
Breast cancer
PI3KαH1047R(next gen)
Breast cancer
PI3Kα E542K, E545K
To be announced
PI3Kα E542K, E545K
To be announced
Undisclosed
To be announced
Undisclosed
Oncogene target
To be announced
Bocodepsin
{em}NRAS{/em} Melanoma{sup}(1){/sup}
Bocodepsin
Oral, selective class I
HDAC inhibitor
{em}NRAS{/em} Melanoma{sup}(1){/sup}
In combination w/ binimetinib
Nautilus Trial
Pfizer logo
Class I HDAC inhibition has been shown to dramatically enhance the efficacy of MEK inhibitors in Ras pathway driven melanomas by coordinately suppressing two DNA repair pathways. A potential clinical biomarker that predicts responsiveness has also been identified.

(1) Bocodepsin (OKI-179) Phase 1 first-in-human single agent trial previously completed.

(2) Pursuant to a Clinical Trial Collaboration and Supply Agreement with Pfizer for binimetinib/bocodepsin combination; OnKure retains all bocodepsin commercial rights.